Would you offer a mid-treatment transition from transtuzumab to TDM-1 for a patient already on 1 year of adjuvant trastuzumab who met criteria for adjuvant TDM-1 based on the KATHERINE trial?   

Any factors that would impact this decision (how far along adjuvant trastuzumab, disease characteristics, etc)?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice